Unlike in the ccRCC cohort, in the pRCC cohort AR-FL, AR-V1 and AR-V3 had more frequent expression in tumors (tumor expression > normal expression in 56%, 89%, and 56% of samples, respectively), while AR-V4 and AR-V7 expression dominated in control tissues (tumor expression < normal expression in 56% of samples for both variants) (Table 3). The gene discussed is AR; the disease is nonpapillary renal cell carcinoma.